Table 4 Association of CASP8 polymorphism, haplotypes and diplotypes with breast cancer risk, the clinico-pathological features and overall survival
Characteristics | Polymorphism/ Haplotype/ Diplotype | P-value Adj. a | OR/HR (95%CI) Adj | D’ |
|---|---|---|---|---|
Breast cancer risk | rs3834129 (II + ID vs. DD) | 0.034 | 1.76 (1.04–2.97) |  |
Breast cancer risk | rs3834129 (ID + DD vs. II) | 0.014 | 1.58 (1.09–2.67) |  |
Breast cancer risk | rs2037815 (GA + GG vs. AA) | 0.031 | 1.44 (1.03–2.01) |  |
Breast cancer risk | rs7608692 (GA + AA vs. GG) | 0.006 | 1.47 (1.12–1.93) |  |
Breast cancer risk | rs3754934 (CA + AA vs. CC) | 0.004 | 0.49 (0.27–0.78) |  |
Breast cancer risk | rs10931936 (CT + TT vs. CC) | < 0.001 | 2.06 (1.44–2.93) |  |
Breast cancer risk | Haplotype rs3817578-rs10931936- rs1045485 (CTG vs. Others) | < 0.001 | 1.78 (1.32–2.41) | 0.52 |
Breast cancer risk | Haplotype rs3754934-rs3817578-rs10931936-rs1045485 (CCTG vs. Others) | < 0.001 | 1.75 (1.30–2.38) | 0.61 |
Breast cancer risk | Haplotype rs3754934-rs3817578-rs10931936-rs1045485 (ATCG vs. Others) | 0.007 | 0.43 (0.24–0.79) | 0.61 |
Breast cancer risk | Haplotype rs3754934-rs381757-rs10931936-rs1045485-rs1045487 (CCCGG vs. Others) | 0.03 | 0.77 (0.60–0.97) | 0.62 |
Breast cancer risk | Haplotype rs3754934-rs381757-rs10931936-rs1045485-rs1045487 (CCTGG vs. Others) | 0.004 | 1.58 (1.16–2.14) | 0.62 |
Breast cancer risk | Haplotype rs12990906-rs3769821-rs6435074-rs3754934-rs3817578-rs10931936 (CTCCCC vs. Others) | 0.011 | 0.71 (0.54–0.92) | 0.59 |
Breast cancer risk | Diplotype rs3817578-rs10931936- rs1045485 (CCG-CTG) vs. Others) | 0.004 | 2.01 (1.25–3.22) |  |
Breast cancer risk | Diplotype rs3817578-rs10931936- rs1045485 (CCC, CTG) vs. Others) | < 0.001 | 5.04 (2.17–11.71) |  |
Breast cancer risk | Diplotype rs3754934-rs3817578-rs10931936-rs1045485 (CCCG-CCTG vs. Others) | 0.007 | 1.93 (1.38–2.80) |  |
Breast cancer risk | Diplotype rs3754934-rs381757-rs10931936-rs1045485-rs1045487 (CCCGG-CCTGG) vs. Others) | 0.019 | 1.78 (1.10–2.90) |  |
Age of diagnosis | rs1045487(AA vs. GG) | 0.022 | 0.37 (0.14–0.97) |  |
Age of menarche | rs3834129 (Ins/Del vs. Ins/Ins) | 0.034 | 0.83 (0.72–0.96) |  |
Age of menarche | rs2037815 (AA vs. GG) | 0.026 | 0.79 (0.64–0.97) |  |
BMI | rs13113 (AA vs. TT) | 0.029 | 0.92 (0.87–0.98) |  |
ER (Pos. vs. Neg.) | rs3754934 (CA vs. CC) | 0.008 | 0.40 (0.20–0.78) |  |
ER/PR + vs. TNBC | rs7608692 (AA vs. GG) | 0.039 | 1.56 (1.03–2.36) |  |
ER (Pos. vs. Neg.) | Haplotype rs3754934-rs3817578-rs10931936-rs1045485 (ATCG vs. Others) | < 0.001 | 0.25 (0.12–0.51) | 0.61 |
BMI | Diplotype rs12990906- rs3769821-rs6435074-rs3754934-rs3817578-rs10931936 (TTCCCC-TTCCCC vs. Others) | 0.004 | 1.04 (1.02–1.07) |  |
Stage (Late vs. Early) | Diplotype rs12990906-rs3769821-rs6435074-rs3754934-rs3817578-rs10931936 (TTCCCC-CTCCCC vs. Others) | 0.017 | 3.21 (1.23–8.37) |  |
Her2 (Pos. vs. Neg.) | Diplotype rs6435074-rs3754934-rs3817578-rs10931936-rs1045485-rs1045487 (CCCCGG, ACCTGG vs. Others) | 0.043 | 1.96 (1.02–3.78) |  |